SFAM

Springhill Fund Asset Management Portfolio holdings

AUM $20.9M
This Fund
S&P 500
This Quarter Est. Return
1 Year Est. Return
–
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$20.9M
AUM Growth
-$40.7M
Cap. Flow
Cap. Flow %
Top 10 Hldgs %
Holding
30
New
Increased
Reduced
Closed

Top Buys

1
+$2.49M
2
+$1.84M
3
+$1.79M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$1.72M
5
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$1.29M

Top Sells

1
+$6.21M
2
+$6.15M
3
+$5.56M
4
AZN icon
AstraZeneca
AZN
+$5.01M
5
VERA icon
Vera Therapeutics
VERA
+$4.63M

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRNA
1
DELISTED
Verona Pharma
VRNA
$4.03M 19.32%
63,499
-71,953
SMMT icon
2
Summit Therapeutics
SMMT
$12.5B
$2.4M 11.49%
+124,307
JANX icon
3
Janux Therapeutics
JANX
$826M
$2.12M 10.16%
78,500
+48,900
REGN icon
4
Regeneron Pharmaceuticals
REGN
$78.8B
$1.65M 7.9%
+2,600
NBIX icon
5
Neurocrine Biosciences
NBIX
$13B
$1.51M 7.21%
+13,612
INSM icon
6
Insmed
INSM
$30.1B
$1.46M 7.02%
19,192
-50,308
SLNO icon
7
Soleno Therapeutics
SLNO
$1.74B
$1.42M 6.8%
19,858
+18,065
JAZZ icon
8
Jazz Pharmaceuticals
JAZZ
$11B
$1.22M 5.86%
+9,853
AKRO
9
DELISTED
Akero Therapeutics
AKRO
$807K 3.87%
19,925
-131,275
ARGX icon
10
argenx
ARGX
$43.3B
$678K 3.25%
+1,146
LLY icon
11
Eli Lilly
LLY
$880B
$674K 3.23%
+816
PTGX icon
12
Protagonist Therapeutics
PTGX
$5.89B
$622K 2.98%
+12,859
TGTX icon
13
TG Therapeutics
TGTX
$4.46B
$532K 2.55%
+13,500
TARS icon
14
Tarsus Pharmaceuticals
TARS
$2.89B
$363K 1.74%
+7,076
ASND icon
15
Ascendis Pharma
ASND
$13.9B
$339K 1.62%
+2,173
RYTM icon
16
Rhythm Pharmaceuticals
RYTM
$5.97B
$332K 1.59%
+6,277
BNTX icon
17
BioNTech
BNTX
$22.9B
$273K 1.31%
+3,000
SWTX
18
DELISTED
SpringWorks Therapeutics
SWTX
$260K 1.25%
+5,897
COGT icon
19
Cogent Biosciences
COGT
$5.52B
$177K 0.85%
29,491
-519,063
ABVX
20
Abivax
ABVX
$9.13B
– –
-207,600
AZN icon
21
AstraZeneca
AZN
$295B
– –
-76,500
BCYC
22
Bicycle Therapeutics
BCYC
$332M
– –
-116,400
CGEM icon
23
Cullinan Oncology
CGEM
$797M
– –
-276,400
CYTK icon
24
Cytokinetics
CYTK
$7.4B
– –
-130,735
DRUG
25
Bright Minds Biosciences
DRUG
$705M
– –
-60,648
1
2